A 56-week, randomized, double-blind, placebo-controlled, multinational, multicenter trial with 396 participants (SCALETM Insulin, NCT02963922) [30] showed that overweight individuals or individuals with obesity, all of which were insulin-treated for T2DM, increased weight loss compared to placebo when liraglutide was added as an adjunct to intensive behavioral therapy (IBT). The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.